- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2012-06-29 19:58:02
- Reporting Period:
- Filing Date:
- Accepted Time:
- 2012-06-29 18:58:02
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1382911||Orexigen Therapeutics Inc.||OREX||Pharmaceutical Preparations (2834)||651178822|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1380022||Michael Narachi||C/o Orexigen Therapeutics, Inc. |
3344 N. Torrey Pines Court, Suite 200
La Jolla CA 92037
|President And Ceo||Yes||Yes||No||No|
Reported Non-Derivative Transactions
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
Reported Derivative Transactions
|Sec. Name||Sec. Type||Acquisiton - Disposition||Date||Amount||Price||Amount - 2||Price - 2|
|Common Stock||Stock Option (right to buy)||Disposition||2012-06-28||100,000||$0.00||100,000||$1.66|
|Common Stock||Stock Option (right to buy)||Disposition||2012-06-29||125,000||$0.00||125,000||$1.66|
|Remaning Holdings||Exercise Date||Expiration Date||Equity Swap Involved||Transaction Form Type||Transaction Code||Nature of Ownership|
- The exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2012.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2012.
- 1/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) (which option is referred to in this Form 4 as the "Replacement Grant") shall vest on the same day of each one-month period of the reporting persons service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the reporting persons continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
- Not applicable.